AVXL 10 Year Annualized Return and Average Annual Return

The AVXL 10 year annualized return is -7.45% with dividends reinvested through 10/09/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows AVXL average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
AVXL Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into AVXL

Also see:
• AVXL stock yearly return 2016
• AVXL stock yearly return 2017
• AVXL stock yearly return 2018
• AVXL stock yearly return 2019
• AVXL stock yearly return 2020
• AVXL stock yearly return 2021
• AVXL stock yearly return 2022
• AVXL stock yearly return 2023
• AVXL stock yearly return 2024
• AVXL stock yearly return 2025
• AVXL YTD return
Average Annual Return Benchmarks
Compare AVXL average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
AVXL Share Performance
AVXL Average Annual Return Table 10 Years
Start date: 10/11/2016
End date: 10/09/2026
Start price/share: $3.23
End price/share: $1.49
Dividends collected/share: $0.00
Total return: -53.87%
AVXL Average Annual Return: -7.45%
Starting investment: $10,000.00
Ending investment: $4,610.67
Years: 10.00


AVXL average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Anavex Life Sciences Corp
Anavex Life Sciences is a clinical stage biopharmaceutical company engaged in the development of therapeutics by applying medicine to central nervous system diseases. Co.'s proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with certain modes of action, based on its understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer's disease, as well as of neurodevelopmental nature, like Rett syndrome. Compounds that have been subjects of Co.'s research include the following: ANAVEX®2-73 (blarcamesine), ANAVEX®3-71, ANAVEX®1-41, and ANAVEX®1066, ANAVEX®1037. The AVXL average annual return 10 years is shown above.

The Average Annual Return on the AVXL average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether AVXL average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the AVXL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
AVXL Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree AVXL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Anavex Life Sciences (AVXL) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

AXGN Average Annual Return
AXSM Average Annual Return
AYTU Average Annual Return
AZN Average Annual Return
BAX Average Annual Return
BBIO Average Annual Return
BBLG Average Annual Return
BCAB Average Annual Return
BCDA Average Annual Return
BCLI Average Annual Return
More Healthcare companies »
What has the average annual return been for AVXL over the past ten years?
✔️Accepted answer: The ten year AVXL average annual return has been -7.45%.

What start date was used in your AVXL average annual return calculation?
✔️Accepted answer: The start date was 10/11/2016.

What end date was used in your AVXL average annual return calculation?
✔️Accepted answer: The end date was 10/09/2026.

If I had invested $10,000 into AVXL ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 10/09/2026, you would have $4,610.67.

What does that work out to on a total return basis?
✔️Accepted answer: The AVXL ten year total return ending 10/09/2026 works out to -53.87%.


Also see:
• AVXL stock yearly return 2016
• AVXL stock yearly return 2017
• AVXL stock yearly return 2018
• AVXL stock yearly return 2019
• AVXL stock yearly return 2020
• AVXL stock yearly return 2021
• AVXL stock yearly return 2022
• AVXL stock yearly return 2023
• AVXL stock yearly return 2024
• AVXL stock yearly return 2025
• AVXL YTD return
 

AVXL 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.